SuperworthAEON Biopharma EPS AEON
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$3.59
- Latest quarter, Q2 FY26
- −$0.02
- Fiscal year 2025
- −$1.60
- −102% on the year before
AEON Biopharma's earnings per share was −$3.59 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.02.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.60 | −102% |
| FY2024 | $68.47 | +428% |
| FY2022 | $12.96 | −47% |
| FY2021 | $24.48 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.02 | n/a | −$3.59 | |
| Q1 FY26 | −$0.29 | −113% | −$4.17 | |
| Q4 FY25 | −$2.89 | −181% | −$1.60 | |
| Q3 FY25 | −$0.39 | n/a | $4.87 | |
| Q2 FY25 | −$0.60 | −100% | −$5.98 | |
| Q1 FY25 | $2.28 | n/a | $298.62 | |
| Q4 FY24 | $3.58 | n/a | $68.47 | |
| Q3 FY24 | −$11.24 | n/a | n/a | |
| Q2 FY24 | $304.00 | n/a | n/a | |
| Q1 FY24 | −$227.87 | n/a | n/a | |
| Q2 FY23 | −$7.92 | −320% | −$13.68 | |
| Q1 FY23 | −$9.36 | −263% | −$2.16 |
Against its peers
Companies in Drug Manufacturers - General nearest AEON Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AEONAEON Biopharma | −$3.59 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on AEON Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.